Novo Nordisk

Ranked second in the list of largest companies in the EU is Novo Nordisk. Novo Nordisk A/S is a Danish multinational pharmaceutical firm based in Bagsvaerd, Denmark, with manufacturing sites in nine countries and affiliates or offices in five. Novo Nordisk is owned by Novo Holdings A/S, which owns around 25% of the company's shares and a relative majority (45%) of its voting shares. Novo Nordisk develops and sells pharmaceutical products and services, mostly diabetic drugs and equipment. Novo Nordisk also works on hemostasis, growth hormone therapy, and hormone replacement therapy.

The mission of Novo Nordisk is to drive change in order to overcome diabetes and other significant chronic diseases such as obesity, rare blood and rare endocrine diseases. They accomplish this by pioneering scientific breakthroughs, increasing access to our medicines, and trying to prevent and eventually cure the diseases we treat. They employ over 50,000 individuals in 80 offices worldwide and sell our products in 170 countries. They are the first pharmaceutical business to employ only renewable energy in all of their global manufacturing sites.

It is quite rare for a company among the world's major pharmaceutical players to concentrate on just one medical problem. Novo Nordisk is one of these unusual companies, focusing nearly entirely on the development of diabetic medications and therapies. The company's headquarters are in a Copenhagen suburb. The Scandinavian country is a pharmaceutical powerhouse, especially given its small size. Novo Nordisk is arguably the most well-known Danish firm in the world, and the country's second largest in terms of sales, trailing only transportation and logistics behemoth Maersk.

Founded: 1923
Headquarters: Bagsvaerd, Denmark
Website: https://www.novonordisk.com/